Changes in Inflammatory and Atherogenesis Biomarkers With the 2-Drug Regimen Dolutegravir Plus Lamivudine in Antiretroviral Therapy-Experienced, Virologically Suppressed People With HIV-1: A Systematic Literature Review
| العنوان: | Changes in Inflammatory and Atherogenesis Biomarkers With the 2-Drug Regimen Dolutegravir Plus Lamivudine in Antiretroviral Therapy-Experienced, Virologically Suppressed People With HIV-1: A Systematic Literature Review |
|---|---|
| المؤلفون: | Llibre, JM, Cahn, PE, Lo, J, Barber, TJ, Mussini, C, van Welzen, BJ, Hernandez, B, Donovan, C, Kisare, M, Sithamparanathan, M, van Wyk, J |
| المصدر: | Open Forum Infectious Diseases r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol instname |
| بيانات النشر: | Oxford University Press, 2022. |
| سنة النشر: | 2022 |
| مصطلحات موضوعية: | dolutegravir plus lamivudine, inflammation, 2-drug regimen, HIV-1 |
| الوصف: | Background The 2-drug regimen dolutegravir plus lamivudine has demonstrated long-term noninferior efficacy vs 3-/4-drug regimens (3/4DRs) in phase 3 trials. This systematic literature review summarizes clinical trial and real-world evidence evaluating impact of dolutegravir plus lamivudine on inflammatory and atherogenesis biomarkers in people with human immunodeficiency virus type 1 (PWH). Methods Using Ovid MEDLINE, Embase, PubMed, and Cochrane library databases and conference proceedings, we searched for studies published from 1 January 2013 to 14 July 2021, reporting changes in inflammatory and atherogenesis biomarkers with dolutegravir plus lamivudine in antiretroviral therapy-experienced, virologically suppressed PWH aged >= 18 years. Results Four records representing 2 randomized controlled trials (RCTs) and 6 records of real-world evidence met eligibility criteria. All real-world studies evaluated CD4(+)/CD8(+) ratio, while only 1 assessed inflammatory biomarkers. Across both RCTs, no consistent pattern of change in biomarkers was observed between dolutegravir/lamivudine and 3/4DR comparators. There were significant changes in soluble CD14 favoring dolutegravir/lamivudine in TANGO at weeks 48 and 144 and SALSA at week 48, and in interleukin-6 favoring the control group in TANGO at weeks 48 and 144. In the real-world study evaluating inflammatory biomarkers, median soluble CD14 significantly decreased 48 weeks postswitch to dolutegravir plus lamivudine (P < .001), while other biomarkers remained stable. In all 6 real-world studies, increases in CD4(+)/CD8(+) ratio were reported after switch to dolutegravir plus lamivudine (follow-up, 12-60 months). Conclusions Results show that dolutegravir plus lamivudine has a comparable impact on inflammatory and atherogenesis biomarkers vs 3/4DRs, with no consistent pattern of change after switch in virologically suppressed PWH. Results from this systematic literature review show that the 2-drug regimen of dolutegravir plus lamivudine has a comparable impact on inflammatory and atherogenesis biomarkers vs 3- or 4-drug regimen comparators, with no consistent reproducible pattern of change. |
| تدمد: | 2328-8957 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::76bf63fb45b14db4d786377dc181f908 https://fundanet.igtp.cat/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=7161 |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.RECOLECTA.....76bf63fb45b14db4d786377dc181f908 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 23288957 |
|---|